Anti-DHRS3 monoclonal antibody
Pre-made anti-DHRS3 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to DHRS3/DHRS3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP0690-Ab-1/ GM-Tg-hg-IP0690-Ab-2 | Anti-Human DHRS3 monoclonal antibody | Human |
GM-Tg-rg-IP0690-Ab-1/ GM-Tg-rg-IP0690-Ab-2 | Anti-Rat DHRS3 monoclonal antibody | Rat |
GM-Tg-mg-IP0690-Ab-1/ GM-Tg-mg-IP0690-Ab-2 | Anti-Mouse DHRS3 monoclonal antibody | Mouse |
GM-Tg-cynog-IP0690-Ab-1/ GM-Tg-cynog-IP0690-Ab-2 | Anti-Cynomolgus/ Rhesus macaque DHRS3 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP0690-Ab-1/ GM-Tg-felg-IP0690-Ab-2 | Anti-Feline DHRS3 monoclonal antibody | Feline |
GM-Tg-cang-IP0690-Ab-1/ GM-Tg-cang-IP0690-Ab-2 | Anti-Canine DHRS3 monoclonal antibody | Canine |
GM-Tg-bovg-IP0690-Ab-1/ GM-Tg-bovg-IP0690-Ab-2 | Anti-Bovine DHRS3 monoclonal antibody | Bovine |
GM-Tg-equg-IP0690-Ab-1/ GM-Tg-equg-IP0690-Ab-2 | Anti-Equine DHRS3 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP0690-Ab-1/ GM-Tg-hg-IP0690-Ab-2; GM-Tg-rg-IP0690-Ab-1/ GM-Tg-rg-IP0690-Ab-2; GM-Tg-mg-IP0690-Ab-1/ GM-Tg-mg-IP0690-Ab-2; GM-Tg-cynog-IP0690-Ab-1/ GM-Tg-cynog-IP0690-Ab-2; GM-Tg-felg-IP0690-Ab-1/ GM-Tg-felg-IP0690-Ab-2; GM-Tg-cang-IP0690-Ab-1/ GM-Tg-cang-IP0690-Ab-2; GM-Tg-bovg-IP0690-Ab-1/ GM-Tg-bovg-IP0690-Ab-2; GM-Tg-equg-IP0690-Ab-1/ GM-Tg-equg-IP0690-Ab-2 |
Products Name | Anti-DHRS3 monoclonal antibody |
Format | mab |
Target Name | DHRS3 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-DHRS3 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP0690-Ag-1 | Recombinant multi-species DHRS3/ DD83.1/ RDH17 protein |
ORF Viral Vector | pGMLP002499 | human DHRS3 Lentivirus plasmid |
ORF Viral Vector | vGMLP002499 | human DHRS3 Lentivirus particle |
ORF Viral Vector | pGMLPm002595 | mouse Dhrs3 Lentivirus plasmid |
ORF Viral Vector | vGMLPm002595 | mouse Dhrs3 Lentivirus particle |
Target information
Target ID | GM-IP0690 |
Target Name | DHRS3 |
Gene ID | 9249,20148,313689,715548,487436,101080307,281482,100055537 |
Gene Symbol and Synonyms | CNALPTC1,DD83.1,DHRS3,RDH17,retSDR1,Rsdr1,SDR1,SDR16C1 |
Uniprot Accession | O75911,O77769 |
Uniprot Entry Name | DHRS3_HUMAN,DHRS3_BOVIN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000162496 |
Target Classification | N/A |
The target: DHRS3, gene name: DHRS3, also named as DD83.1, RDH17, Rsdr1, SDR1, SDR16C1, retSDR1. Short-chain dehydrogenases/reductases (SDRs), such as DHRS3, catalyze the oxidation/reduction of a wide range of substrates, including retinoids and steroids (Haeseleer and Palczewski, 2000 [PubMed 10800688]).[supplied by OMIM, Jun 2009].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.